Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Center, Single-Arm Clinical Study to Evaluate the Novel Humanized Cluster of Differentiation 38(CD38) Monoclonal Antibody (CM313) for the Treatment of Pemphigus

NCT06904040 is registered in ClinicalTrials.gov with Sichuan Provincial People's Hospital as lead sponsor.

NCT NCT06904040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06904040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Center, Single-Arm Clinical Study to Evaluate the Novel Humanized Cluster of Differentiation 38(CD38) Monoclonal Antibody (CM313) for the Treatment of Pemphigus
Lead sponsor
Sichuan Provincial People's Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
April 1, 2025
Completion date
April 1, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pemphigus